Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Sarah Avent

- PMLiVE

Novavax’s XBB.1.5-adapted COVID-19 vaccine receives EC approval

Individuals aged 12 years and older will be eligible to receive the updated COVID-19 vaccine

- PMLiVE

GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

GSK will evaluate the therapy in combination with its own hepatitis B treatment

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Evoke appoints Cris Morton as group president

Morton was most recently group president at Havas Health & You

- PMLiVE

Building a behaviour change survival kit: making strategy stick

Mastering behaviour change is a necessity but for many of our clients it represents some of their biggest challenges

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education

- PMLiVE

Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

- PMLiVE

Boehringer Ingelheim reveals new corporate branding

The evolved brand includes the company’s first-ever brand claim, Life Forward

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

bluebird bio to sell FDA priority review voucher for $103m

The company previously sold its second voucher to Bristol Myers Squibb for $95m

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in long-term chronic hand eczema study

There are currently no topical treatments specifically approved for moderate-to-severe CHE

- PMLiVE

Innovative Trials has been shortlisted in the PMEA Awards

Innovative Trials finalist in the Support Agency of the Year at the annual PMEA industry awards.

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links